Mammary‐analog secretory carcinoma in children: Surgery or TRK inhibitors first?
http://api.archives-ouvertes.fr/search/?fq=halId_s:hal-04453140&fl=title_s,en_title_s,docid,label_s,en_label_s,docType_s,authIdHal_s,halId_s,structId_i,uri_s,keyword_s,en_keyword_s,authLastNameFirstName_s,journalTitle_s,abstract_s,en_abstract_s,producedDate_tdate,producedDateY_i,language_s,fileMain_s&sort=publicationDate_s+desc
authors
keywords
- NTRK fusion
- TRK inhibitor
- Entrectinib
- Larotrectinib
- Mammary analog secretory carcinoma
document type
ARTabstract
Abstract We report two cases of pediatric mammary‐analog secretory carcinoma (MASC), a male operated on at age 8 and a female operated on at 12, who are in remission 2 years after surgery. The diagnosis of MASC was challenging and established by identifying the ETV6::NTRK3 fusion transcript in both cases. Given the excellent results of TRK inhibitor treatments in adult MASC and pediatric tumors expressing an ETV6::NTRK3 fusion, they should probably be prescribed as first‐line treatment in cases requiring surgery with foreseeable serious sequelae or metastatic disease.
Aix Marseille Université | All rights reserved - Legal notice